Telix (TLX) 6-K adds TLX250-CDx and H1 2025 OPEX data

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited submitted a Form 6-K summarizing two announcements it filed with the Australian Securities Exchange in August 2025. One announcement, dated August 28, 2025, provides a regulatory update on its TLX250-CDx program. The other, dated August 5, 2025, presents historical financials in U.S. dollars and unaudited operating expenses for the first half of 2025. Both announcements are attached as exhibits to the Form 6-K.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2025

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On August 28, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited (the “Company”) filed an announcement with the Australian Securities Exchange (“ASX”) titled “Telix Provides Regulatory Update on TLX250-CDx,” a copy of which is attached to this Form 6-K as Exhibit 99.1.

On August 5, 2025 (Melbourne, Australia), the Company filed an announcement with the ASX titled “Historical Financials in USD and H12025 OPEX (Unaudited),” a copy of which is attached to this Form 6-K as Exhibit 99.2.

99.1	Press release – August 28, 2025
99.2	Press release – August 5, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: August 28, 2025	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

FAQ

What does Telix Pharmaceuticals (TLX) report in this Form 6-K?

The Form 6-K from Telix Pharmaceuticals Limited furnishes two Australian Securities Exchange announcements: a regulatory update on TLX250-CDx dated August 28, 2025, and a release on historical financials in USD and unaudited H1 2025 operating expenses dated August 5, 2025.

What is included in the TLX250-CDx regulatory update mentioned by Telix (TLX)?

The Form 6-K states that Telix filed an ASX announcement titled “Telix Provides Regulatory Update on TLX250-CDx” on August 28, 2025, and that this announcement is attached as Exhibit 99.1 to the report.

What financial information does Telix (TLX) provide in the attached exhibits?

Telix includes an ASX announcement titled “Historical Financials in USD and H12025 OPEX (Unaudited)”, dated August 5, 2025, as Exhibit 99.2, which covers historical financials in U.S. dollars and unaudited operating expenses for the first half of 2025.

Where are Telix’s August 2025 ASX announcements available in the 6-K?

The ASX announcement on the TLX250-CDx regulatory update is attached as Exhibit 99.1, and the announcement on historical financials in USD and H1 2025 OPEX (unaudited) is attached as Exhibit 99.2 to the Form 6-K.

Who signed the August 2025 Form 6-K for Telix Pharmaceuticals (TLX)?

The Form 6-K is signed on behalf of Telix Pharmaceuticals Limited by Genevieve Ryan, who is identified as the Company Secretary, dated August 28, 2025.